17:55 EST Vertex Pharmaceuticals (VRTX) up 2% at $448 after FDA Journavx approval
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals’ non-opioid painkiller approved by FDA, Bloomberg says
- Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
- Meta Platforms, CVS Health upgraded: Wall Street’s top analyst calls
- Wells downgrades Vertex to Equal Weight on lack of catalysts
- Vertex downgraded to Equal Weight from Overweight at Wells Fargo